436 related articles for article (PubMed ID: 37445827)
21. Biochemical and Biological Attributes of Matrix Metalloproteinases.
Cui N; Hu M; Khalil RA
Prog Mol Biol Transl Sci; 2017; 147():1-73. PubMed ID: 28413025
[TBL] [Abstract][Full Text] [Related]
22. [The role of metalloproteinases in modification of extracellular matrix in invasive tumor growth, metastasis and angiogenesis].
Fink K; Boratyński J
Postepy Hig Med Dosw (Online); 2012 Sep; 66():609-28. PubMed ID: 23001203
[TBL] [Abstract][Full Text] [Related]
23. Regulation and involvement of matrix metalloproteinases in vascular diseases.
Amin M; Pushpakumar S; Muradashvili N; Kundu S; Tyagi SC; Sen U
Front Biosci (Landmark Ed); 2016 Jan; 21(1):89-118. PubMed ID: 26709763
[TBL] [Abstract][Full Text] [Related]
24. Matrix metalloproteinases and their inhibitors.
Kugler A
Anticancer Res; 1999; 19(2C):1589-92. PubMed ID: 10365151
[TBL] [Abstract][Full Text] [Related]
25. Matrix metalloproteinases in exercise and obesity.
Jaoude J; Koh Y
Vasc Health Risk Manag; 2016; 12():287-95. PubMed ID: 27471391
[TBL] [Abstract][Full Text] [Related]
26. Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum.
Vaillant C; Didier-Bazès M; Hutter A; Belin MF; Thomasset N
J Neurosci; 1999 Jun; 19(12):4994-5004. PubMed ID: 10366632
[TBL] [Abstract][Full Text] [Related]
27. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis.
Sutinen M; Kainulainen T; Hurskainen T; Vesterlund E; Alexander JP; Overall CM; Sorsa T; Salo T
Br J Cancer; 1998 Jun; 77(12):2239-45. PubMed ID: 9649139
[TBL] [Abstract][Full Text] [Related]
28. Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.
Benjamin MM; Khalil RA
Exp Suppl; 2012; 103():209-79. PubMed ID: 22642194
[TBL] [Abstract][Full Text] [Related]
29. The functional balance of metalloproteinases and inhibitors in tissue degradation: relevance to oral pathologies.
Reynolds JJ; Meikle MC
J R Coll Surg Edinb; 1997 Jun; 42(3):154-60. PubMed ID: 9195805
[TBL] [Abstract][Full Text] [Related]
30. Differential regulation of the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases by cytokines and growth factors in bovine endometrial stromal cells and trophoblast cell line BT-1 in vitro.
Hirata M; Sato T; Tsumagari M; Shimada A; Nakano H; Hashizume K; Ito A
Biol Reprod; 2003 Apr; 68(4):1276-81. PubMed ID: 12606436
[TBL] [Abstract][Full Text] [Related]
31. The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer.
Gallegos NC; Smales C; Savage FJ; Hembry RM; Boulos PB
Surg Oncol; 1995; 4(2):111-9. PubMed ID: 7551259
[TBL] [Abstract][Full Text] [Related]
32. Dynamic interdomain interactions contribute to the inhibition of matrix metalloproteinases by tissue inhibitors of metalloproteinases.
Remacle AG; Shiryaev SA; Radichev IA; Rozanov DV; Stec B; Strongin AY
J Biol Chem; 2011 Jun; 286(23):21002-12. PubMed ID: 21518756
[TBL] [Abstract][Full Text] [Related]
33. Role of the matrix metalloproteinase and tissue inhibitors of metalloproteinase families in noninvasive and invasive tumors transplanted in mice with severe combined immunodeficiency.
Furukawa A; Tsuji M; Nishitani M; Kanda K; Inoue Y; Kanayama H; Kagawa S
Urology; 1998 May; 51(5):849-53. PubMed ID: 9610608
[TBL] [Abstract][Full Text] [Related]
34. Expression and modulation of matrix metalloproteinase-2 and tissue inhibitors of metalloproteinases in human embryonic CNS stem cells.
Frölichsthal-Schoeller P; Vescovi AL; Krekoski CA; Murphy G; Edwards DR; Forsyth P
Neuroreport; 1999 Feb; 10(2):345-51. PubMed ID: 10203333
[TBL] [Abstract][Full Text] [Related]
35. The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer.
Gallegos NC; Smales C; Savage FJ; Hembry RM; Boulos PB
Surg Oncol; 1995 Feb; 4(1):21-9. PubMed ID: 7780609
[TBL] [Abstract][Full Text] [Related]
36. Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis.
Hembry RM; Bagga MR; Reynolds JJ; Hamblen DL
Ann Rheum Dis; 1995 Jan; 54(1):25-32. PubMed ID: 7880117
[TBL] [Abstract][Full Text] [Related]
37. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer.
Gress TM; Müller-Pillasch F; Lerch MM; Friess H; Büchler M; Adler G
Int J Cancer; 1995 Aug; 62(4):407-13. PubMed ID: 7635566
[TBL] [Abstract][Full Text] [Related]
38. Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.
Kucukguven A; Khalil RA
Curr Drug Targets; 2013 Mar; 14(3):287-324. PubMed ID: 23316963
[TBL] [Abstract][Full Text] [Related]
39. Role of matrix metalloproteinases and their inhibitors in tumor invasion and metastasis.
Khasigov PZ; Podobed OV; Gracheva TS; Salbiev KD; Grachev SV; Berezov TT
Biochemistry (Mosc); 2003 Jul; 68(7):711-7. PubMed ID: 12946252
[TBL] [Abstract][Full Text] [Related]
40. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain.
Rosenberg GA; Estrada EY; Dencoff JE
Stroke; 1998 Oct; 29(10):2189-95. PubMed ID: 9756602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
